Page last updated: 2024-09-04

cyc 202 and Cirrhosis, Liver

cyc 202 has been researched along with Cirrhosis, Liver in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Chen, KX; Fan, S; Fu, R; Huang, H; Huang, J; Li, GM; Li, J; Liao, L; Liu, Y; Luo, C; Shi, C; Yu, L; Zhang, YY	1

Other Studies

1 other study(ies) available for cyc 202 and Cirrhosis, Liver

Article	Year
Cyclin-dependent kinase inhibitor roscovitine attenuates liver inflammation and fibrosis by influencing initiating steps of liver injury. Clinical science (London, England : 1979), 2021, 04-16, Volume: 135, Issue:7 Topics: Animals; Carbon Tetrachloride; Cell Line; Chemical and Drug Induced Liver Injury; Galactosamine; Humans; Inflammation; Lipopolysaccharides; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Protein Kinase Inhibitors; RAW 264.7 Cells; Roscovitine; Sequence Analysis, RNA	2021

Article

Year

Cyclin-dependent kinase inhibitor roscovitine attenuates liver inflammation and fibrosis by influencing initiating steps of liver injury.

Clinical science (London, England : 1979), 2021, 04-16, Volume: 135, Issue:7

Topics: Animals; Carbon Tetrachloride; Cell Line; Chemical and Drug Induced Liver Injury; Galactosamine; Humans; Inflammation; Lipopolysaccharides; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Protein Kinase Inhibitors; RAW 264.7 Cells; Roscovitine; Sequence Analysis, RNA

2021